FDA Pediatric Incentives, Powers Would Become Permanent Under Draft Bill

In the absence of sunset provisions that necessitate periodic reauthorization of the pediatric laws, GAO would report to Congress on a five-year cycle about the accomplishments of the drug programs for children and make recommendations for amendments.